



### Question 1

---

Bellinva S, Edwards CJ. Explaining biosimilars and how reverse engineering plays a critical role in their development. *Expert Opin Drug Discov.* 2020;15(11):1283-1289.

Huizinga TWJ, Torii Y, Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. *Rheumatol Ther.* 2021;8(1):41-61.

Lemery SJ, Esteva FJ, Weise M. Biosimilars: here and now. *Am Soc Clin Oncol Educ Book.* 2016;35:e151-7.

### Question 2

---

Christl L. FDA's overview of the regulatory guidance for the development and approval of biosimilar products in the US. Available at [www.fda.gov/files/drugs/published/FDA%E2%80%99s-Overview-of-the-Regulatory-Guidance-for-the-Development-and-Approval-of-Biosimilar-Products-in-the-US.pdf](http://www.fda.gov/files/drugs/published/FDA%E2%80%99s-Overview-of-the-Regulatory-Guidance-for-the-Development-and-Approval-of-Biosimilar-Products-in-the-US.pdf). Accessed September 30, 2021.

FDA. Biosimilar and interchangeable biologics: more treatment choices. Available at [www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices](http://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices). Accessed September 30, 2021.

Lemery SJ, Esteva FJ, Weise M. Biosimilars: here and now. *Am Soc Clin Oncol Educ Book.* 2016;35:e151-7.

Moore TJ, Mouslim MC, Blunt JL, Alexander GC, Shermock KM. Assessment of availability, clinical testing, and US Food and Drug Administration review of biosimilar biologic products. *JAMA Intern Med.* 2021;181(1):52-60.

### Question 3

---

Akram MS, Pery N, Butler L, Shafiq MI, Batool N, Rehman MFU, Grahame-Dunn LG, Yetisen AK. Challenges for biosimilars: focus on rheumatoid arthritis. *Crit Rev Biotechnol.* 2021;41(1):121-153.

Bellinva S, Edwards CJ. Explaining biosimilars and how reverse engineering plays a critical role in their development. *Expert Opin Drug Discov.* 2020;15(11):1283-1289.

Bielsky MC, Cook A, Wallington A, Exley A, Kauser S, Hay JL, Both L, Brown D. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. *Drug Discov Today.* 2020:S1359-6446(20)30343-3.

Moore TJ, Mouslim MC, Blunt JL, Alexander GC, Shermock KM. Assessment of availability, clinical testing, and US Food and Drug Administration review of biosimilar biologic products. *JAMA Intern Med.* 2021;181(1):52-60.

### Question 4

---

Christl L. FDA's overview of the regulatory guidance for the development and approval of biosimilar products in the US. Available at [www.fda.gov/files/drugs/published/FDA%E2%80%99s-Overview-of-the-Regulatory-Guidance-for-the-Development-and-Approval-of-Biosimilar-Products-in-the-US.pdf](http://www.fda.gov/files/drugs/published/FDA%E2%80%99s-Overview-of-the-Regulatory-Guidance-for-the-Development-and-Approval-of-Biosimilar-Products-in-the-US.pdf). Accessed September 30, 2021.

FDA. Biosimilar and interchangeable biologics: more treatment choices. Available at [www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices](http://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices). Accessed September 30, 2021.

FDA. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Available at [www.fda.gov/media/70958/download](http://www.fda.gov/media/70958/download). Accessed September 30, 2021.

Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. *Ann Rheum Dis.* 2018;77(2):165-174.

Park W, Lee SJ, Yun J, Yoo DH. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. *Expert Rev Clin Immunol.* 2015;11 Suppl 1:S25-31.

# Reference List



## *The Ultimate Quiz Show on the Science of Biosimilars*

### Question 5

---

FDA. Biosimilar and interchangeable biologics: more treatment choices. Available at [www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices](http://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices). Accessed September 30, 2021.

FDA. Biosimilar development, review, and approval. Available at [www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval](http://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval). Accessed September 30, 2021

Bielsky MC, Cook A, Wallington A, Exley A, Kauser S, Hay JL, Both L, Brown D. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. *Drug Discov Today*. 2020;S1359-6446(20)30343-3.

### Question 6

---

Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. *Ann Rheum Dis*. 2018;77(2):165-174.

Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, Plasencia C, Balsa A, Llinares-Tello F, Rosas J, Torres N, Martínez A, Nagore D. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. *Ann Rheum Dis*. 2016;75(9):1693-6.

### Question 7

---

FDA. Biosimilar product information. Available at [www.fda.gov/drugs/biosimilars/biosimilar-product-information](http://www.fda.gov/drugs/biosimilars/biosimilar-product-information). Accessed October 9, 2021.

Gherghescu I, Delgado-Charro MB. The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. *Pharmaceutics*. 2020 Dec 31;13(1):48.

Stempel J. Amgen patents on top-selling arthritis drug Enbrel upheld, shares rise. <https://www.reuters.com/article/amgen-novartis-enbrel/amgen-patents-on-top-selling-arthritis-drug-enbrel-upheld-shares-rise-idINKBN2426D6>. Accessed October 9, 2021.

### Question 8

---

FDA. Biosimilar product information. Available at [www.fda.gov/drugs/biosimilars/biosimilar-product-information](http://www.fda.gov/drugs/biosimilars/biosimilar-product-information). Accessed October 9, 2021.

Socal MP, Ezebilu I, Bai G, Anderson GF. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab. *Am J Health Syst Pharm*. 2021 Jan 22;78(3):216-221.

Yazdany J. Failure to launch: biosimilar sales continue to fall flat in the United States. *Arthritis Rheumatol*. 2020 Jun;72(6):870-873.

### Question 9

---

Biologic Prescribers Collaborative. Patients' understanding of biological medicines: survey findings. Available at [www.biologicsprescribers.org/wp-content/uploads/2020/03/BPC\\_Survey-Report\\_March-2020.pdf](http://www.biologicsprescribers.org/wp-content/uploads/2020/03/BPC_Survey-Report_March-2020.pdf). Accessed October 9, 2021.

Socal MP, Ezebilu I, Bai G, Anderson GF. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab. *Am J Health Syst Pharm*. 2021 Jan 22;78(3):216-221.

### Question 10

---

Gibofsky A, McCabe D. US rheumatologists' beliefs and knowledge about biosimilars: a survey. *Rheumatology*. 2021;60(2):896-901.

Kim SC, Sarpatwari A, Landon JE, Desai RJ. Utilization and treatment costs of tumor necrosis factor inhibitors after the introduction of biosimilar infliximab in the United States. *Arthritis Rheumatol*. 2020;72(6):1036-1038.

Moore TJ, Mouslim MC, Blunt JL, Alexander GC, Shermock KM. Assessment of availability, clinical testing, and US Food and Drug Administration review of biosimilar biologic products. *JAMA Intern Med*. 2021;181(1):52-60.